BioCentury
ARTICLE | Clinical News

GLPG2222: Phase I data

June 27, 2016 7:00 AM UTC

A double-blind, placebo-controlled, Belgian Phase I trial in about 40 healthy volunteers showed that single ascending doses of up to 800 mg oral GLPG2222 and once-daily ascending doses of up to 600 mg...